Factor VII Deficiency, Healthy Participants, Hemophilia A, Hemophilia B
Conditions
Keywords
Single ascending dose, Multiple ascending dose, Factor IX, Factor VIII, Factor VII
Brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B).
Detailed description
This is a first-in-human (FIH) study to be conducted with SR604. The study will enroll healthy participants (Part A) and participants with Hemophilia A or Hemophilia B or FVII deficiency (Part B). In Part A (single ascending dose \[SAD\]): Healthy participants will be randomized in a 2:1 ratio in each of the 3 to 4 (Cohort 4 is optional) sequential cohorts. All cohorts will include participants receiving active treatment with SR604 and the other participant receiving matching placebo. In Part B (multiple ascending dose \[MAD\]): Participants with Hemophilia A or Hemophilia B or FVII deficiency, with or without inhibitors, will be enrolled in 4 cohorts with four dose levels and is planned to receive SR604 subcutaneously. The overall duration of study participation will be approximately 3 months.
Interventions
DRUGSR604
SR604 will be administered as SC injection.
DRUGPlacebo
Placebo will be administered as single SC injection.
Sponsors
Equilibra Bioscience LLC
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: Part A: * Male participants aged 18 to 55 years, inclusive. * Body mass index between 18 and 30 kilograms per meter square (kg/m\^2), inclusive, and weighs greater than or equal to (\>=) 50 kilograms (kg), less than or equal to (\<=) 90 kg. * No clinically significant findings on medical examination, including physical examination, 12-lead electrocardiogram, and clinical laboratory tests. * Sexually active men must commit to use an effective method of birth control while taking the study intervention and for 90 days after the dose of study intervention. Part B: * Male and female participants (only female participants with congenital FVII deficiency) aged 18 to 60 years, inclusive. * Participants must have one of the following bleeding disorders: Severe hemophilia A (\<1% Factor VIII \[FVIII\]); or Severe and/or moderately severe Hemophilia B (≤ 2% Factor IX \[FIX\]); or Severe FVII deficiency (\<10% FVII activity). Participants with severe FVII deficiency must satisfy with either of following criteria: 1. Participants with history of \>2 bleeding events in the last 12 months require on-demand treatment with recombinant factor VIIa (rFVIIa) or plasma-derived FVII concentrates (pd-FVII) or fresh frozen plasma (FFP) for bleeding control. 2. Participants on prophylaxis treatment with rFVIIa or pd-FVII or FFP regardless of bleeding history. * Participants with Hemophilia A or Hemophilia B must satisfy either of the following criteria: 1. Participants not on prophylaxis must have a documented ABR of 6 in 12 months before screening. 2. Participants on prophylaxis must have a documented ABR of ≥ 2 in 12 months before screening. 3. Intolerant to current treatment regimen. * Medical records documenting a minimum of 2 years of bleeding event history. * Willing to undergo a weaning period from prior treatment or prophylaxis for Hemophilia A or Hemophilia B or FVII deficiency. * Sexually active men must commit to use an effective method of birth control while taking the study intervention and for 90 days after the dose of SR604. * Women of childbearing potential must have a negative pregnancy test at the Screening Visit and agree to follow the contraception guidance during the intervention period and for at least 90 days after the last dose of SR604. Key
Exclusion criteria
Part A: * Participant has clinically significant history or evidence of cardiovascular, respiratory (including all chronic lung diseases), hepatic, renal, gastrointestinal, endocrine, neurological, immunological, bleeding, or psychiatric disorder(s). * Participant has a mean pulse less than (\<) 40 or greater than (\>) 90 beats per minute (bpm), mean systolic blod pressure (BP) \< 90 millimeter of mercury (mmHg) or \> 140 mmHg, or mean diastolic BP \< 50 mmHg or \> 90 mmHg at the screening visit. * Participant has a mean corrected QT corrected for heart rate by Fridericia's formula (QTcF) of \> 450 msec at the Screening Visit. * Participant has had injury, trauma, and/or major surgery within 3 months before Screening, or is planned to undergo surgery during the study. * Participant has received vaccination within 14 days before the dose of study intervention or has a vaccination planned during the study. * History of one or more of the following in participants and/or family members: 1. Factor V (FV) Leiden mutation. 2. Activated protein C (APC) resistant. 3. Protein C (PC) or protein S (PS) deficiency. 4. Prothrombin 20210 mutation; 5. Antithrombin III (ATIII) deficiency. * History of clinically significant intracranial hemorrhage, pneumonia, chronic liver disease, liver or kidney transplants, or malignant diseases. * Any medical condition (eg, diabetes, obesity.) which, in the Investigator's opinion, could compromise participant safety, interfere with study intervention metabolism, or put the study outcome at undue risk. Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant or could prevent, limit or confound protocol-specified assessments. * Participants with a history of all types of thrombosis, including any arterial and/or venous thrombosis, superficial thrombophlebitis, or embolism. Additionally, participants with a history of thrombotic microangiopathy, stroke, and transient ischemic attack (TIA), or abnormal findings in any prior laboratory thrombophilia evaluation will be excluded. Part B: * Participants with a history of all types of thrombosis, including any arterial and/or venous thrombosis, superficial thrombophlebitis, or embolism. Additionally, participants with a history of thrombotic microangiopathy, stroke, and TIA, or abnormal findings in any prior laboratory thrombophilia evaluation will be excluded. * History of one or more of the following in participants and/or family members: 1. FV Leiden mutation. 2. APC resistant. 3. PC or PS deficiency. 4. Prothrombin 20210 mutation. 5. ATIII deficiency. * Impaired cardiac function or clinically significant cardiac disease, including any of the following: 1. Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (New York Heart Association Grade \>=2), left ventricular ejection fraction \< 50% as determined by multiple gated acquisition or echocardiogram, or clinically significant arrhythmia. 2. QTcF \> 450 ms ECG or congenital Long QT Syndrome at the Screening Visit. 3. Acute myocardial infarction or unstable angina pectoris \< 3 months prior to study entry. * Uncontrolled hypertension (systolic BP \> 150 mmHg and diastolic BP \> 100 mmHg), a history of hypertension crisis, or a history of hypertensive encephalopathy. * Participant with the following laboratory abnormalities: 1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 1.5 × upper limit of normal (ULN); 2. Total bilirubin ˃3.0 × ULN and direct bilirubin ˃1.5 × ULN (unless due to Gilbert's syndrome). * Calculated creatinine clearance ˂ 60 mL/min using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula at the Screening Visit. * Participant has positive test result for human immunodeficiency virus (HIV) antibody. 1. If participants test positive for hepatitis B core antibody (HBcAb), additional tests including hepatitis B surface antibody, hepatitis B surface antigen (HBsAg), and hepatitis B viral deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) will be conducted to determine if there is an active infection. Participants with active infection will be excluded from the study. 2. Participants who test positive for hepatitis C virus antibody will be required to have a negative result for hepatitis C viral ribonucleic acid (RNA) PCR before enrollment. Individuals with positive results for hepatitis C PCR will be excluded from the study. * Chronic liver disease (Child-Pugh class C hepatic impairment), or history of liver or kidney transplants. * Injury, trauma, and/or major surgery (mediastinoscopy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery), major dental procedures (extractions, etc.) within 4 weeks of the first dose of SR604 or planned surgery during the study. * Active infection requiring systemic antibiotic or antiviral therapy or in a sepsis condition within 14 days prior to the first dose of SR604. * Any medical condition (eg, diabetes, obesity) which, in the Investigator's opinion, could compromise participant safety, interfere with SR604 metabolism, or put the study outcome at undue risk. * Female participants who are pregnant or are currently breastfeeding or planning to become pregnant while enrolled in this study or within 90 days after the last dose of SR604.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Parts A and B: Number of Participants with Clinical Abnormal Changes in Coagulations Markers | Part A: From Baseline (Day 1) till Day 57; Part B: From Baseline (Day 1) till Day 90 | Safety and tolerability of a single ascending SC dose of SR604 in healthy participants and multiple ascending SC doses of SR604 in participants with Hemophilia A or Hemophilia B or FVII deficiency will be evaluated. |
| Parts A and B: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to 3 months | Safety and tolerability of a single ascending SC dose of SR604 in healthy participants and multiple ascending SC doses of SR604 in participants with Hemophilia A or Hemophilia B or FVII deficiency will be evaluated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Volume of Distribution in Terminal Phase Following Extravascular Administration (Vz/F) of SR604 | From Baseline (Day 1) up to Day 57 | The PK profile (Vz/F) of a single ascending SC dose of SR604 in healthy participants will be assessed. |
| Parts B: Concentration before the next dose administration (Ctrough) | From Baseline (Day 1) up to Day 90 | The PK profile (Ctrough) of SR604 following repeated SC injections will be assessed. |
| Parts B: Accumulation Ratio (R) of SR604 | From Baseline (Day 1) up to Day 90 | The PK profile (accumulation R) of SR604 following repeated SC injections will be assessed. |
| Parts B: Number of Bleeding Events | From Baseline (Day 1) up to 3 months | The preliminary clinical activity of SR604 will be assessed. Bleeding event (record traumatic or non-traumatic bleeding, number of bleeding sites \[joints or non-joints\], bleeding frequency (intervals), associated with any external triggers, level of physical activity) will be evaluated. |
| Parts B: Annualized Bleeding Rate (ABR) in Body and Targeted Joints | From Baseline (Day 1) up to 3 months | The preliminary clinical activity of SR604 will be assessed. ABR in body and targeted joined will be evaluated. |
| Parts A and B: Number of Participants with Positive Antidrug Antibodies (ADAs) | Part A: From Baseline (Day 1) till Day 57; Part B: From Baseline (Day 1) till Day 90 | Number of participants with positive ADAs will be assessed. |
| Parts A and B: Time to Maximum Concentration (tmax) of SR604 | Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to Day 90 | The PK profile (tmax) of a single ascending and multiple ascending SC dose of SR604 will be assessed. |
| Part A: Area Under the Serum Concentration-time Curve from time Zero Extrapolated to Infinity (AUC[0-inf]) | From Baseline (Day 1) up to Day 57 | The PK profile (AUC\[0-inf\]) of a single ascending SC dose of SR604 in healthy participants will be assessed. |
| Parts A and B: Maximum Concentration (Cmax) of SR604 | Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to Day 90 | The PK profile (Cmax) of a single ascending and multiple ascending SC dose of SR604 will be assessed. |
| Parts A and B: Terminal Half-life (T1/2) of SR604 | Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to Day 90 | The PK profile (T1/2) of a single ascending and multiple ascending SC dose of SR604 will be assessed. |
| Part A: Area Under the Serum Concentration-time Curve from time Zero to the Last Quantifiable Time Point (AUC[0-t]) | From Baseline (Day 1) up to Day 57 | The PK profile (AUC\[0-t\]) of a single ascending SC dose of SR604 in healthy participants will be assessed. |
| Part A: Clearance Following Extravascular Administration (CL/F) of SR604 | From Baseline (Day 1) up to Day 57 | The PK profile (CL/F) of a single ascending SC dose of SR604 in healthy participants will be assessed. |
Countries
Canada, United States
Contacts
CONTACTClinical Trials
Outcome results
None listed